Symptomatic and Asymptomatic SARS-CoV-2 Infection and Follow-up of Neutralizing Antibody Levels

OBJECTIVE: To investigate neutralizing antibody levels in symptomatic and asymptomatic patients with coronavirus disease 2019 (COVID-19) at 6 and 10 months after disease onset. METHODS: Blood samples were collected at three different time points from 27 asymptomatic individuals and 69 symptomatic pa...

Descripción completa

Detalles Bibliográficos
Autores principales: CUI, Shu Juan, ZHANG, Yi, GAO, Wen Jing, WANG, Xiao Li, YANG, Peng, WANG, Quan Yi, PANG, Xing Huo, ZENG, Xiao Peng, LI, Li Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Editorial Board of Biomedical and Environmental Sciences. Published by Elsevier (Singapore) Pte Ltd. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850449/
https://www.ncbi.nlm.nih.gov/pubmed/36597289
http://dx.doi.org/10.3967/bes2022.139
Descripción
Sumario:OBJECTIVE: To investigate neutralizing antibody levels in symptomatic and asymptomatic patients with coronavirus disease 2019 (COVID-19) at 6 and 10 months after disease onset. METHODS: Blood samples were collected at three different time points from 27 asymptomatic individuals and 69 symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Virus-neutralizing antibody titers against SARS-CoV-2 in both groups were measured and statistically analyzed. RESULTS: The symptomatic and asymptomatic groups had higher neutralizing antibodies at 3 months and 1–2 months post polymerase chain reaction confirmation, respectively. However, neutralizing antibodies in both groups dropped significantly to lower levels at 6 months post-PCR confirmation. CONCLUSION: Continued monitoring of symptomatic and asymptomatic individuals with COVID-19 is key to controlling the infection.

Ejemplares similares